查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790178

美國即時診斷分子診斷市場規模、佔有率和趨勢分析報告：按技術、應用、檢測地點、最終用途和細分市場預測，2025 年至 2033 年

U.S. Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location, By Application, By Technology, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國POC 分子診斷市場價值將達到 32.3 億美元，預計 2025 年至 2033 年的複合年成長率為 5.45%。

該市場以快速、分散的分子檢測為中心，旨在支持在照護端或照護端附近更快地做出臨床決策。由於門診病人和急診護理環境中對快速、準確結果的需求，這些診斷平台在傳染病篩檢、呼吸道感染疾病和性行為感染感染檢測等應用中的應用日益廣泛。

市場成長的動力源自於傳統實驗室之外，尤其是在急診和診所，對快速便捷檢測的需求日益成長。感染疾病病例的增加以及對快速結果的需求，推動了照護現場(POC) 分子檢測的使用。可攜式PCR 儀和簡易樣本處理工具等新技術使這些檢測更加準確、更容易使用。此外，新冠疫情爆發後，人們對快速檢測的關注也推動了市場進一步成長。

此外，基層醫療機構中的即時檢測 (POC) 分子診斷涵蓋了從基礎血糖檢測到更複雜的凝血檢查等廣泛的應用。美國許多診所正在從傳統的實驗室檢測過渡到即時檢測 (POC) 方法，這有助於減少與樣本處理和運輸相關的延誤。這種轉變使得在就診時能夠更快地做出決策，從而更快地獲得結果、降低成本並改善護理。

此外，預計美國老齡人口的成長將推動POC分子診斷產業的成長。根據美國國家癌症研究所的SEER資料庫，38%的女性和43%的男性在一生中會罹患癌症。近三分之二的新發癌症病例發生在65歲或以上的人群中，這表明癌症的可能性隨著老齡化的成長而增加。分子診斷在癌症、感染疾病和心臟病的治療中發揮重要作用，對於老年人的及時診斷和治療至關重要。

此外，市場上的公司正在積極開發新的即時檢測（POC）分子檢測產品，以滿足日益成長的診斷需求。 2023年4月，總部位於洛杉磯的Curative公司宣布其分拆公司Sensible Diagnostics將推出桌面PCR檢測平台。該系統旨在約10分鐘內提供實驗室層級的檢測結果，成本與側流抗原檢測相當。該系統旨在用於零售診所、緊急護理中心和其他靠近患者的場所。

2023年8月，Sensible Diagnostics 獲得了約100萬美元的NIH RADx Tech獎項，用於支持開發用於即時診斷的多重呼吸道病毒檢測組。這些努力反映了對快速、準確的分子檢測解決方案的持續投資，這些解決方案支持及時診斷並改善分散醫療環境中的臨床工作流程。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國POC 分子診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國POC分子診斷市場的分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國POC 分子診斷市場：按技術、估計和趨勢分析

  • 波動分析：按技術
  • 基於PCR
    • 基於PCR的市場，2021-2033
  • 基於基因定序
    • 基因定序市場，2021-2033
  • 基於雜合反應
    • 雜合反應動力市場，2021-2033
  • 基於微陣列
    • 2021-2033年微陣列市場

第5章：美國POC 分子診斷市場的應用、估計與趨勢分析

  • 波動分析：按應用
  • 感染疾病
    • 感染疾病市場，2021-2033年
    • HIV POC
    • 困難梭狀芽孢桿菌POC
    • HBV POC
    • 肺炎或鏈球菌感染疾病
    • 呼吸道融合細胞病毒(RSV) 臨床驗證
    • HPV POC
    • 流感/流感 POC
    • HCV POC
    • MRSA POC
    • 結核病和抗藥性結核病的即時治療
    • HSV POC
    • 其他
  • 腫瘤學
    • 腫瘤學市場 2021-2033
  • 血液學
    • 血液學市場 2021-2033
    • 全血球計數（CBC）
    • 凝血酶原時間（PT）
    • 部份凝血活酵素時間（PTT）
    • 其他
  • 產前檢查
    • 產前檢測市場，2021-2033年
  • 內分泌學
    • 內分泌學市場，2021-2033
  • 其他
    • 其他市場，2021-2033

第6章：美國POC 分子診斷市場（按測試地點、估計和趨勢分析）

  • 變異分析：依測試地點
  • OTC
    • 場外交易市場，2021-2033年
  • POC
    • POC市場，2021-2033年

第7章美國POC分子診斷市場：依最終用途的估計和趨勢分析

  • 變化分析：依最終用途
  • 分散式實驗室
    • 分散式實驗室市場，2021-2033
  • 醫院
    • 醫院市場，2021-2033
  • 居家護理
    • 家庭護理市場，2021-2033
  • 輔助生活醫療設施
    • 輔助醫療設施市場，2021-2033
  • 其他
    • 其他市場，2021-2033

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 推出新產品和服務
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市場佔有率分析（2024年）
  • 公司熱圖分析
  • 公司簡介
    • QIAGEN
    • DANAHER
    • THERMO FISHER SCIENTIFIC, INC.
    • BD
    • F. HOFFMAN-LA ROCHE AG
    • CHARLES RIVER LABORATORIES
    • QUEST DIAGNOSTICS INCORPORATED
    • BIO-RAD LABORATORIES, INC.
    • HOLOGIC INC.
    • AGILENT TECHNOLOGIES, INC.
Product Code: GVR-4-68040-203-1

Market Size & Trends:

The U.S. point of care molecular diagnostics market size was estimated at USD 3.23 billion in 2024 and is expected to grow at a CAGR of 5.45% from 2025 to 2033. The market is centered around rapid and decentralized molecular testing that supports quicker clinical decisions at or near the site of patient care. These diagnostic platforms are increasingly adopted for applications such as infectious disease screening, respiratory tract infections, and sexually transmitted disease detection, driven by the need for immediate and accurate results in outpatient and emergency settings.

Market growth is supported by the rising demand for quick and easy testing outside traditional labs, especially in emergency rooms and clinics. The growing number of infectious disease cases and the need for fast results are pushing the use of point-of-care molecular tests. New technologies, such as portable PCR machines and simple sample processing tools, make these tests more accurate and easier to use. In addition, the focus on faster testing after the COVID-19 pandemic is helping the market grow further.

Moreover, point-of-care molecular diagnostics in primary care settings cover a wide range of uses, from basic glucose tests to more complex blood clotting checks. Many clinics across the U.S. are moving away from traditional lab-based testing to point-of-care methods, which help reduce delays linked to sample handling and transport. This switch allows for quicker decisions during patient visits, leading to faster results, lower costs, and improved care.

In addition, the growing elderly population is expected to support the growth of the U.S. point of care molecular diagnostics industry. Based on the U.S. National Cancer Institute's SEER Database, 38% of women and 43% of men are likely to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are found in people aged 65 and older, showing that aging increases vulnerability to cancer. Molecular diagnostics play a key role in managing cancer, infectious diseases, and heart conditions, making them an essential part of timely diagnosis and treatment in older adults.

Furthermore, market players are actively developing new point-of-care molecular testing products to address growing diagnostic needs. In April 2023, Curative, Inc., based in Los Angeles, announced the spin-off of Sensible Diagnostics to commercialize a desktop PCR testing platform. This system is designed to deliver lab-quality results in approximately 10 minutes, at a cost similar to lateral flow antigen tests. It is intended for use in retail clinics, urgent care centers, and other near-patient environments.

In August 2023, Sensible Diagnostics received a NIH RADx Tech award of approximately USD 1 million to support the development of a multiplex respiratory viral panel for point-of-care use. These efforts reflect growing investment in rapid, accurate molecular testing solutions that support timely diagnosis and improve clinical workflows across decentralized care settings.

U.S. Point of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. point of care molecular diagnostics market report based on application, technology, test location, and end-use:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
    • HIV POC
    • Clostridium difficile POC
    • HBV POC
    • Pneumonia or Streptococcus associated infections
    • Respiratory syncytial virus (RSV) POC
    • HPV POC
    • Influenza/Flu POC
    • HCV POC
    • MRSA POC
    • TB and drug-resistant TB POC
    • HSV POC
    • Other Infectious Diseases
  • Oncology
  • Hematology
    • Complete blood count (CBC)
    • Prothrombin time (PT)
    • Partial Thromboplastin Time (PTT)
    • Others
  • Prenatal Testing
  • Endocrinology
  • Other Applications
  • Test Location Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • POC
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Location
    • 1.2.2. Application
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in the U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Location and Application Snapshot
    • 2.2.2. Technology Snapshot
    • 2.2.3. End Use Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Point-of-Care Molecular Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing demand for rapid and decentralized testing
      • 3.2.1.2. Rising prevalence of infectious diseases
      • 3.2.1.3. Technological advancements in molecular platforms
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of molecular POC devices and consumables
      • 3.2.2.2. Regulatory and quality assurance challenges
  • 3.3. U.S. Point-of-Care Molecular Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based market, 2021 - 2033 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based market, 2021 - 2033 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based market, 2021 - 2033 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases market, 2021 - 2033 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC market, 2021 - 2033 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC market, 2021 - 2033 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC market, 2021 - 2033 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections market, 2021 - 2033 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC market, 2021 - 2033 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC market, 2021 - 2033 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC market, 2021 - 2033 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC market, 2021 - 2033 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC market, 2021 - 2033 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC market, 2021 - 2033 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC market, 2021 - 2033 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases market, 2021 - 2033 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology market, 2021 - 2033 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology market, 2021 - 2033 (USD Million)
    • 5.4.2. Complete blood count (CBC)
      • 5.4.2.1. Complete blood count (CBC) market, 2021 - 2033 (USD Million)
    • 5.4.3. Prothrombin time (PT)
      • 5.4.3.1. Prothrombin time (PT) market, 2021 - 2033 (USD Million)
    • 5.4.4. Partial Thromboplastin Time (PTT)
      • 5.4.4.1. Partial Thromboplastin Time (PTT) market, 2021 - 2033 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others market, 2021 - 2033 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing market, 2021 - 2033 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC market, 2021 - 2033 (USD Million)
  • 6.3. POC
    • 6.3.1. POC market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs market, 2021 - 2033 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals market, 2021 - 2033 (USD Million)
  • 7.4. Home-care
    • 7.4.1. Home-care market, 2021 - 2033 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Products and Services Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. QIAGEN
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Products and Services Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. DANAHER
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Products and Services Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. THERMO FISHER SCIENTIFIC, INC.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Products and Services Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BD
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Products and Services Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. F. HOFFMAN-LA ROCHE AG
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Products and Services Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CHARLES RIVER LABORATORIES
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Products and Services Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. QUEST DIAGNOSTICS INCORPORATED
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Products and Services Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. BIO-RAD LABORATORIES, INC.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Products and Services Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. HOLOGIC INC.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Products and Services Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. AGILENT TECHNOLOGIES, INC.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Products and Services Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Point-of-Care Molecular Diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 3 U.S. Point-of-Care Molecular Diagnostics market, by application, 2021- 2033 (USD Million)
  • Table 4 U.S. Point-of-Care Molecular Diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 5 U.S. Point-of-Care Molecular Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in the U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Point-of-Care Molecular Diagnostics market: market outlook
  • Fig. 10 U.S. Point-of-Care Molecular Diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Point-of-Care Molecular Diagnostics market driver impact
  • Fig. 16 U.S. Point-of-Care Molecular Diagnostics market restraint impact
  • Fig. 17 U.S. Point-of-Care Molecular Diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. Point-of-Care Molecular Diagnostics market: Application movement analysis
  • Fig. 19 U.S. Point-of-Care Molecular Diagnostics market: Application outlook and key takeaways
  • Fig. 20 Point-of-Care Molecular Diagnostics Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 21 Point-of-Care Molecular Diagnostics HIV POC market, 2021 - 2033 (USD Million)
  • Fig. 22 Point-of-Care Molecular Diagnostics Clostridium difficile POC market, 2021 - 2033 (USD Million)
  • Fig. 23 Point-of-Care Molecular Diagnostics HBV POC market, 2021 - 2033 (USD Million)
  • Fig. 24 Point-of-Care Molecular Diagnostics Pneumonia or Streptococcus associated infections market, 2021 - 2033 (USD Million)
  • Fig. 25 Point-of-Care Molecular Diagnostics Respiratory syncytial virus (RSV) POC market, 2021 - 2033 (USD Million)
  • Fig. 26 Point-of-Care Molecular Diagnostics HPV POC market, 2021 - 2033 (USD Million)
  • Fig. 27 Point-of-Care Molecular Diagnostics Influenza/Flu POC market, 2021 - 2033 (USD Million)
  • Fig. 28 Point-of-Care Molecular Diagnostics HCV POC market, 2021 - 2033 (USD Million)
  • Fig. 29 Point-of-Care Molecular Diagnostics MRSA POC market, 2021 - 2033 (USD Million)
  • Fig. 30 Point-of-Care Molecular Diagnostics TB and drug-resistant TB POC market, 2021 - 2033 (USD Million)
  • Fig. 31 Point-of-Care Molecular Diagnostics HSV POC market, 2021 - 2033 (USD Million)
  • Fig. 32 Point-of-Care Molecular Diagnostics Other Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 33 Point-of-Care Molecular Diagnostics Oncology market, 2021 - 2033 (USD Million)
  • Fig. 34 Point-of-Care Molecular Diagnostics Hematology market, 2021 - 2033 (USD Million)
  • Fig. 35 Point-of-Care Molecular Diagnostics Complete blood count (CBC) market, 2021 - 2033 (USD Million)
  • Fig. 36 Point-of-Care Molecular Diagnostics Prothrombin time (PT) market, 2021 - 2033 (USD Million)
  • Fig. 37 Point-of-Care Molecular Diagnostics Partial Thromboplastin Time (PTT) market, 2021 - 2033 (USD Million)
  • Fig. 38 Point-of-Care Molecular Diagnostics Others market, 2021 - 2033 (USD Million)
  • Fig. 39 Point-of-Care Molecular Diagnostics Prenatal Testing market, 2021 - 2033 (USD Million)
  • Fig. 40 Point-of-Care Molecular Diagnostics Endocrinology market, 2021 - 2033 (USD Million)
  • Fig. 41 Point-of-Care Molecular Diagnostics Other Applications market, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Point-of-Care Molecular Diagnostics market: Technology movement Analysis
  • Fig. 43 U.S. Point-of-Care Molecular Diagnostics market: Technology outlook and key takeaways
  • Fig. 44 Point-of-Care Molecular Diagnostics PCR-based market, 2021 - 2033 (USD Million)
  • Fig. 45 Point-of-Care Molecular Diagnostics Genetic Sequencing-based market, 2021 - 2033 (USD Million)
  • Fig. 46 Point-of-Care Molecular Diagnostics Hybridization-based market, 2021 - 2033 (USD Million)
  • Fig. 47 Point-of-Care Molecular Diagnostics Microarray-based market, 2021 - 2033 (USD Million)
  • Fig. 48 Point-of-care Molecular Diagnostics revenue share, by test location, 2021 - 2033
  • Fig. 49 Point-of-Care Molecular Diagnostics OTC market, 2021 - 2033 (USD Million)
  • Fig. 50 Point-of-Care Molecular Diagnostics POC market, 2021 - 2033 (USD Million)
  • Fig. 51 U.S. Point-of-Care Molecular Diagnostics market: End Use movement analysis
  • Fig. 52 U.S. Point-of-Care Molecular Diagnostics market: End Use outlook and key takeaways
  • Fig. 53 Point-of-Care Molecular Diagnostics Decentralized Labs market, 2021 - 2033 (USD Million)
  • Fig. 54 Point-of-Care Molecular Diagnostics Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 55 Point-of-Care Molecular Diagnostics Home-care market, 2021 - 2033 (USD Million)
  • Fig. 56 Point-of-Care Molecular Diagnostics Assisted Living Healthcare Facilities market, 2021 - 2033 (USD Million)
  • Fig. 57 Point-of-Care Molecular Diagnostics Other uses market, 2021 - 2033 (USD Million)
  • Fig. 58 U.S. Point-of-Care Molecular Diagnostics market share and leading players
  • Fig. 59 U.S. market share and leading players
  • Fig. 60 U.S. SWOT
  • Fig. 61 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 62 Market share of key market players- U.S. Point-of-Care Molecular Diagnostics market